Zoetis

ZTS

Market cap $55.2B

I rate Zoetis (ZTS) a buy, citing a robust pipeline, upcoming product launches, and discounted valuation versus peers. ZTS targets new therapeutic white spaces—oncology, cardiology, and renal disease—minimizing risk and offering substantial first-mover advantages. The CKD monoclonal antibody for canine renal disease, launching in 2027, could unlock a $3–4 billion market with recurring revenue potential.

Zoetis (ZTS) reached $125.32 at the closing of the latest trading day, reflecting a -1.45% change compared to its last close.

Zoetis Inc. (ZTS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Stephanie Link, chief investment officer at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.

Investors looking for stocks in the Medical - Drugs sector might want to consider either United Therapeutics (UTHR) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-present.

Although the S&P 500 has returned 19.3% so far this year, dozens of stocks are showing significant declines for 2025.

Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to explain why she's buying more Zoetis.

Zoetis (ZTS) closed at $123.78 in the latest trading session, marking a +1.26% move from the prior day.